ArticleEuropean journal of neurology2025
Is a Benign Disease Course Possible in Untreated AQP4-IgG NMOSD?
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A novel limited-dose C5 inhibitor add-on as rescue therapy for refractory NMOSD attacks: a practical alternative to conventional multi-dose regimens.BMC neurology · 2026Article
- Aquaporin-4-IgG positive radiologically isolated neuromyelitis optica spectrum disorder: treat or observe?Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Double-seronegative neuromyelitis optica: it is not possible to interrupt treatment after 10 years of stability.Arquivos de neuro-psiquiatria · 2025Review
- Double-seronegative neuromyelitis optica: it is possible to interrupt treatment after 10 years of stability.Arquivos de neuro-psiquiatria · 2025Review
- SARS-CoV-2 Spike Protein and Molecular Mimicry: An Immunoinformatic Screen for Cross-Reactive Autoantigen Candidates.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMost patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD) require life-long immunosuppression to prevent relapses. Patients who are untreated or undergo de-escalation of therapy typically experience severe disabling relapses. We present a series of patients who, despite not receiving immunosuppression, developed minimal disability.
methodsCase series from a UK national NMOSD referral centre. We defined benign disease as an estimated disability status scale score of ≤ 3 after a minimum of 4 years without immunotherapy.
resultsOf 153 AQP4-IgG NMOSD patients, 8 (5.2%) had a benign disease course after a median follow-up of 7.5 years (Q1: 5.8, Q3: 13.3) without immunotherapy. All patients were female, and 7/8 were of White racial background. Clinical attacks included isolated optic neuritis, transverse myelitis, area postrema syndrome or combinations of these syndromes.
conclusionThe presence of benign NMOSD and the potential for safe de-escalation of therapy in NMOSD remains unclear. This study suggests that both may be possible. Further studies of similar cases could provide valuable insights and identify biomarkers for safe treatment discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.